Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
The fund experienced short-term underperformance in Q1 2026 due to sector rotation away from growth assets, but the managers maintain strong conviction in their high-growth equity holdings and high-quality fixed-income buffer.
Full Quick Take
The fund experienced short-term underperformance in Q1 2026 due to sector rotation away from growth assets, but the managers maintain strong conviction in their high-growth equity holdings and high-quality fixed-income buffer.
Mondrian's strategy outperformed in Q4 2025 with a 7.3% net return, benefiting from strong stock selection in the UK and industrials amid a rotation to defensive sectors.
Full Quick Take
Mondrian's strategy outperformed in Q4 2025 with a 7.3% net return, benefiting from strong stock selection in the UK and industrials amid a rotation to defensive sectors.
Patient Capital's Opportunity Equity Strategy achieved a 25.23% net return in 2024, capitalizing on a late-year rally. The fund remains constructive on the ongoing technological revolution while actively rotating capital away from high-flying cyclicals into neglected pockets of deep value, healthcare, and energy.
Full Quick Take
Patient Capital's Opportunity Equity Strategy achieved a 25.23% net return in 2024, capitalizing on a late-year rally. The fund remains constructive on the ongoing technological revolution while actively rotating capital away from high-flying cyclicals into neglected pockets of deep value, healthcare, and energy.
